Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses

Virology

Volumn 387, Issue 2, 2009, Pages 442-448

  Nakamura, Mitsuhiro ^a,b   Bodily, Jason M ^a   Beglin, Melanie ^a   Kyo, Satoru ^b   Inoue, Masaki ^b   Laimins, Laimonis A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Carbonic anhydrase (CAIX); Deferoxamine mesylate (DFO); Hypoxia; Hypoxia inducible factor 1 (HIF 1); Keratinocytes; Papillomaviruses (HPV); Vascular endothelial growth factor (VEGF)

Indexed keywords

CARBONATE DEHYDRATASE IX; DEFEROXAMINE MESYLATE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; PROTEIN E6; PROTEIN E7; PROTEIN P53; RAPAMYCIN; VASCULOTROPIN;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 31; HYPOXIA; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN STABILITY; VIRUS GENOME; VIRUS ONCOGENE;

CELL HYPOXIA; CELL LINE; DEFEROXAMINE; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KERATINOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTEIN STABILITY; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 64849096447     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.02.036     Document Type: Article

References (58)

1. Abraham R.T. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr. Top. Microbiol. Immunol. 279 (2004) 299-319
2. Alam H., Maizels E.T., Park Y., Ghaey S., Feiger Z.J., Chandel N.S., and Hunzicker-Dunn M. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J. Biol. Chem. 279 19 (2004) 19431-19440
3. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., and Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 6674 (1998) 405-408
4. Bachtiary B., Schindl M., Potter R., Dreier B., Knocke T.H., Hainfellner J.A., Horvat R., and Birner P. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin. Cancer Res. 9 6 (2003) 2234-2240
5. Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., and Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61 4 (1987) 962-971
6. Bardos J.I., and Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta 1755 2 (2005) 107-120
7. Bardos J.I., Chau N.M., and Ashcroft M. Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol. Cell. Biol. 24 7 (2004) 2905-2914
8. Bequet-Romero M., and Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem. Biophys. Res. Commun. 277 1 (2000) 55-61
9. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M.C., Rafii S., and Pandolfi P.P. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442 7104 (2006) 779-785
10. Bischof O., Nacerddine K., and Dejean A. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol. Cell. Biol. 25 3 (2005) 1013-1024
11. Bodily J.M., and Meyers C. Analysis of HPV transcription by RPA. Methods Mol. Med. 119 (2005) 279-290
12. Brat D.J., Kaur B., and Van Meir E.G. Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front. Biosci. 8 (2003) d100-d116
13. Carroll P.A., Kenerson H.L., Yeung R.S., and Lagunoff M. Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. J. Virol. 80 21 (2006) 10802-10812
14. Chen W., Li F., Mead L., White H., Walker J., Ingram D.A., and Roman A. Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology 367 1 (2007) 168-174
15. Clere N., Bermont L., Fauconnet S., Lascombe I., Saunier M., Vettoretti L., Plissonnier M.L., and Mougin C. The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. Exp. Cell Res. 313 15 (2007) 3239-3250
16. Eichten A., Westfall M., Pietenpol J.A., and Munger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology 295 1 (2002) 74-85
17. Evans S.M., Schrlau A.E., Chalian A.A., Zhang P., and Koch C.J. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J. Invest. Dermatol. 126 12 (2006) 2596-2606
18. Fehrmann F., Klumpp D.J., and Laimins L.A. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J. Virol. 77 5 (2003) 2819-2831
19. Halbert C.L., Demers G.W., and Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65 1 (1991) 473-478
20. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996) 353-364
21. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
22. Hebner C.M., Wilson R., Rader J., Bidder M., and Laimins L.A. Human papillomaviruses target the double-stranded RNA protein kinase pathway. J. Gen. Virol. 87 Pt 11 (2006) 3183-3193
23. Huang S.M., and McCance D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 76 17 (2002) 8710-8721
24. Hudson J.B., Bedell M.A., McCance D.J., and Laiminis L.A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J. Virol. 64 2 (1990) 519-526
25. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81 18 (2007) 9737-9747
26. Ishikawa H., Sakurai H., Hasegawa M., Mitsuhashi N., Takahashi M., Masuda N., Nakajima M., Kitamoto Y., Saitoh J., and Nakano T. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 60 2 (2004) 513-521
27. Lee W.Y., Huang S.C., Hsu K.F., Tzeng C.C., and Shen W.L. Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. Gynecol. Oncol. 108 2 (2007) 377-384
28. Longworth M.S., and Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68 2 (2004) 362-372
29. Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., and Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19 40 (2000) 4611-4620
30. Mayer A., Wree A., Hockel M., Leo C., Pilch H., and Vaupel P. Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res. 64 16 (2004) 5876-5881
31. Mazibrada J., Ritta M., Mondini M., De Andrea M., Azzimonti B., Borgogna C., Ciotti M., Orlando A., Surico N., Chiusa L., Landolfo S., and Gariglio M. Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol. Oncol. 108 1 (2008) 112-120
32. Meyers C., and Laimins L.A. In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 186 (1994) 199-215
33. Moody C.A., Fradet-Turcotte A., Archambault J., and Laimins L.A. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl. Acad. Sci. U. S. A. 104 49 (2007) 19541-19546
34. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., and Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78 21 (2004) 11451-11460
35. O'Brien P.M., and Saveria Campo M. Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res. 88 1-2 (2002) 103-117
36. Oh S.T., Longworth M.S., and Laimins L.A. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J. Virol. 78 5 (2004) 2620-2626
37. Rader J.S., Golub T.R., Hudson J.B., Patel D., Bedell M.A., and Laimins L.A. In vitro differentiation of epithelial cells from cervical neoplasias resembles in vivo lesions. Oncogene 5 4 (1990) 571-576
38. Rankin E.B., and Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15 4 (2008) 678-685
39. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14 1 (2000) 34-44
40. Rempe D.A., Lelli K.M., Vangeison G., Johnson R.S., and Federoff H.J. In cultured astrocytes, p53 and MDM2 do not alter hypoxia-inducible factor-1alpha function regardless of the presence of DNA damage. J. Biol. Chem. 282 22 (2007) 16187-16201
41. Ruesch M.N., and Laimins L.A. Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium. Virology 250 1 (1998) 19-29
42. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 6 (1990) 1129-1136
43. Schmid T., Zhou J., Kohl R., and Brune B. p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem. J. 380 Pt 1 (2004) 289-295
44. Smith-McCune K., Zhu Y.H., Hanahan D., and Arbeit J. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res. 57 7 (1997) 1294-1300
45. Smith-McCune K.K., and Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 54 3 (1994) 800-804
46. Suprynowicz F.A., Sparkowski J., Baege A., and Schlegel R. E5 oncoprotein mutants activate phosphoinositide 3-kinase independently of platelet-derived growth factor receptor activation. J. Biol. Chem. 275 7 (2000) 5111-5119
47. Tang X., Zhang Q., Nishitani J., Brown J., Shi S., and Le A.D. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. 13 9 (2007) 2568-2576
48. Thomas J.T., and Laimins L.A. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J. Virol. 72 2 (1998) 1131-1137
49. Toussaint-Smith E., Donner D.B., and Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23 17 (2004) 2988-2995
50. Webster K., Parish J., Pandya M., Stern P.L., Clarke A.R., and Gaston K. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J. Biol. Chem. 275 1 (2000) 87-94
51. Wilson R., Fehrmann F., and Laimins L.A. Role of the E1^E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J. Virol. 79 11 (2005) 6732-6740
52. Wilson R., and Laimins L.A. Differentiation of HPV-containing cells using organotypic "raft" culture or methylcellulose. Methods Mol. Med. 119 (2005) 157-169
53. Woodworth C.D., Cheng S., Simpson S., Hamacher L., Chow L.T., Broker T.R., and DiPaolo J.A. Recombinant retroviruses encoding human papillomavirus type 18 E6 and E7 genes stimulate proliferation and delay differentiation of human keratinocytes early after infection. Oncogene 7 4 (1992) 619-626
54. Zhang B., Spandau D.F., and Roman A. E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J. Virol. 76 1 (2002) 220-231
55. Zhou J., Schmid T., Schnitzer S., and Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 237 1 (2006) 10-21
56. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 10 (2006) 715-727
57. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1288 2 (1996) F55-F78
58. zur Hausen H. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 111 6 (1999) 581-587